

Accelerator Based Neutron Capture Therapies

AB-NCT

A project of a demonstrator in France

Daniel Santos

Laboratoire de Physique Subatomique et de Cosmologie

LPSC- Université Grenoble-Alpes ,CNRS/IN2P3

Contributions: M. Baylac, F. Bouly, R. Delorme, D. Dauvergne, V. Ghetta, J. Giraud, O. Guillaudin, T. Lamy, J.F. Muraz, P. Rubiolo, N. Sauzet.


Presentation Plan

- ✓ Interest of an AB-NCT project
- ✓ AB-NCT Demonstrator Project in France
- ✓ LPSC contributions to the Project
 - Targets (^9Be , ^7Li) (J. Giraud's talk tomorrow)
 - Beam Shaping Assemblies (BSAs)
 - Fast and thermal neutron detection (N. Sauzet's talk tomorrow)
 - Gamma detector for on-line dose mapping (D. Dauvergne's talk tomorrow)
 - Radiobiology studies and experiments.(U. Koester's talk tomorrow)
- ✓ AB-NCT French project strategy.

Sending epithermal neutrons ($E_n < 10$ keV)

the dose keeps low !

$H_p(d)$: Total dose absorbed by a tissue at a depth d $h = H / n^0$ fluence






ICRP, 1996. Conversion Coefficients for use in Radiological Protection against External Radiation. ICRP Publication 74. Ann. ICRP 26 (3-4). <http://www.icrp.org/publication.asp?id=ICRP%20Publication%2074>

BNCT : Two approved carriers BPA and BSH (healthy tissue / tumoral tissue) between 3 to 4.



BSH : *sodium borocaptate*

BPA : *para-borophenylalanine*




BPA pharmacokinetics

From Kiger et al, *Journal of Neuro-Oncology* 62: 171–186, 2003.





Kaplan-Meier estimates of overall survival for all newly diagnosed glioblastoma (WHO grade 4, n = 21). The median survival time of boron neutron capture therapy (BNCT) group (blue line) is 15.6 months. There is statistical significance between both group Log-rank test ($p = 0.0035$)



Kaplan-Meier estimates of overall survival for all newly diagnosed glioblastoma (protocol 1 and 2). External beam X-ray irradiation (XRT) boost after boron neutron capture therapy (BNCT) was carried for the latter 11 cases. This improved the median survival time to 23.5 months (from 14.1 months for BNCT only, protocol 1, dotted line in blue).

The BNCT has been experimented in USA, Japan, UK, Russia, Finland, Italy, Argentina, China... but never in France




MIT reactor facility

NuPECC 2014 Report: Operative BNCT centres today !

Table 10.1. Operative BNCT centres

Centre	States	Neutron source	N° of treated patients*
Helsinki University Central Hospital, Helsinki, Finland	Europe	FIR-1, VTT Technical Research Centre, Espoo	50 GM 2 AA 31 HN
University of Tsukuba, Tsukuba City, Ibaraki	Japan	JRR-4, Japan Atomic Energy Agency, Tokai, Ibaraki	20 GM 4 AA
University of Tokushima, Tokushima	Japan	JRR-4 (Kyoto University Research Reactor, Osaka)	23
Osaka Medical College and Kyoto University Research Reactor, Kyoto University, Osaka and Kawasaki Medical School, Kurashiki	Japan	KURR	60 GBM 3 AA 7 Men 124 HN
Taipei Veterans General Hospital, Taipei, Taiwan	Republic of China	THOR, National Tsing Hua University, Hsinchu, Taiwan	10
Instituto de Oncología Angel H, Buenos Aires	Argentina	Bariloche Atomic Center	7CM 3 AT



**Only
Nuclear
Reactors
!**

* GM: glioblastoma multiforme; CM: cutaneous melanoma; AA: anaplastic astrocytoma; HN: head and neck cancer; Men: meningioma; AT: anaplastic thyroid cancer

TARGETS CHOICE



Accelerator based BNCT: Neutron-producing targets

Reaction	Bombarding energy (MeV)	Neutron producing rate (n/sec-mA)	Average neutron energy (keV)	Maximum Neutron energy (keV)	Target melting point (°C)	Target thermal conductivity (W/(m·K))
${}^7\text{Li}(p,n)$	1.91	$2.4 \cdot 10^{10}$	34	67.1	181	71
${}^7\text{Li}(p,n)$	2.5	$8.9 \cdot 10^{11}$	326	786		
${}^9\text{Be}(p,n)$	4	10^{12}	1060	2120	1287	201
${}^9\text{Be}(d,n)$	1.5	$2.16 \cdot 10^{11}$	2010	5810		
${}^{13}\text{C}(d,n)$	1.5	$1.82 \cdot 10^{11}$	1080	6770	3550	230



Lithium “fragility”



Larger the neutron energies,
harder to moderate them....

Accelerators and Targets of the present AB-NCT projects worldwide

Current status and performance of the different accelerators intended for AB-BNCT facilities worldwide.

Institute-location	Machine (status)	Target and reaction	Beam energy (MeV)	Beam Current (mA)	Reference
Budker Institute Russia	Vacuum insulated Tandem (ready)	Solid ${}^7\text{Li}(p,n)$	2.0	2	Aleynik et al (2011)
IPPE-Obninsk Russia	Cascade generator KG-2.5 (ready)	Solid ${}^7\text{Li}(p,n)$	2.3	3	Kononov et al. (2004)
Birmingham Univ. UK	Dynamitron (ready)	Solid ${}^7\text{Li}(p,n)$	2.8	1	Culbertson et al. (2004)
KURRI Japan	Cyclotron (ready)	${}^9\text{Be}(p,n)$	30	1	Tanaka et al. (2011)
Soreq Israel	RFQ-DTL (ready)	Liquid ${}^7\text{Li}(p,n)$	4	1	Halfon et al. (2011)
Legnaro INFN Italy	RFQ (under construction)	${}^9\text{Be}(p,n)$	4-5	30	Ceballos et al. (2011)
Tsukuba Japan	RFQ-DTL (under construction)	${}^9\text{Be}(p,n)$	8	10	Kumada et al. (2011)
CNEA	Single ended	${}^9\text{Be}(d,n)$	1.4	30	Kreiner et al. (2011)
Argentina	Tandem Electrostatic Quadrupole (under construction)	Solid ${}^7\text{Li}(p,n)$	2.5	30	

NIM 2013, Kreiner et al.


AB-NCT Challenges:

- To bring $10^9 n_{th}/(\text{cm}^2.\text{sec})$ to the tumor (30' irradiation time) using a compact and safe facility installed at a hospital.
- To build a target coping with 30-50 kW on 10 cm^2 (3-5 kW/cm²)
- Characterizing the neutron fields getting out the targets and the moderators (Beam Shapping Assemblies)

Project of an AB-NCT demonstrator in France

Two possibilities :

- 1) deuterons (1,5 MeV) on a ^9Be target
- 2) protons (2,5 MeV) on a liquid ^7Li target



Targets and Thermal Test Facility

Target for deuteron beam on ^9Be layer

Current status :

Target material : Beryllium layer



Backing material : Graphite

Backing diameter : 1000 mm


Thermal power dissipated : 30 kW

Cooling of the backing material : radiation mechanism

Regeneration of target



- The targets must work in acceptable thermal conditions
must dissipate the thermal power



- Total thermal power on the targets: 30- 50 kW (on 10 cm²)

Power density of 3- 5 kW/cm²




- Problem : How could we produce this thermal power density ?




Using an electron beam line :

- Energy : 30-50 keV
- Current : 100 mA
- Beam spot size : 1 cm²


- Compact beam line
- Ions or electrons
- \rightarrow 50 keV



- COMIMAC coupled to the test target




- Experimental area and radiation shielding at the LPSC




Moderation and detection of fast and thermal neutrons


Simulation of a BSA for the ^9Be target (M.Tacca, D.S et al. (LPSC,2015))



Neutron spectrum getting out the BSA around the ^9Be target
simulated by Geant4 and MCNP
(M. Tacca, D.S et al. LPSC,2015)




Dose in 1 hour with 10mA



Dose calculation on the tumor and on the healthy tissue in 1 hour irradiation (10 mA of deuterons on the ^9Be target) (contrast factor: 3,5)


We need to improve a factor 6.4 the dose at the tumor...
But the design of the Be target has been improved since then...

Dose in 1 hour with 10mA in healthy tissue




^7Li liquid target

Simulation and dose calculation using the ^7Li target (M.Tacca, D.S. et al (LPSC-2015))



All the quality parameters are fulfilled !!



Free beam parameter	<i>Li</i> BSA	Recommended
ϕ_{epi} (n/cm^2s)	$1,07 + 08 mA^{-1}$	$> 1,00E + 09$
$\dot{D}_{fast}/\phi_{epi}$ ($Gy.cm^2$)	$9,88E - 14$	$< 2,00E - 13$
$\dot{D}_{\gamma}/\phi_{epi}$ ($Gy.cm^2$)	$9,13E - 14$	$< 2,00E - 13$
ϕ_{th}/ϕ_{epi}	0,02	$< 0,05$
J_{tot}/ϕ_{tot}	0,59	$> 0,7$



MIMAC-FastN: fast neutron detector

Neutron monochromatic field:


AMANDE facility at IRSN of Cadarache

- Neutrons with a well defined energy from resonances of ${}^7\text{Li}(p,n)$ reaction

$$E_{\text{Recoil}} = 4 \frac{m_n m_R}{(m_n + m_R)^2} E_{\text{neutron}} \cos^2 \theta$$



D. Maire *et al.*, IEEE transactions on nuclear science, vol. 61, (2014)
arXiv:1310.6837






MIMAC-FastN: A fast neutron directional detector

To characterize the neutron fields produced at the target and at the phantom

^{10}B layer inside the detector volume

One measures the fragments produced by the neutron capture at the “tumor position”

Track length vs. Recoil Energy



N. Sauzet et al, (2015)

Radiobiology experiments and simulations

- In collaboration with the **ESRF** (*ID-17, H. Elleaume*) and the **ILL** (*U. Koester*) :
 - **Experimental studies and dosimetry of different biochemical compounds :**
 - ✓ Cells experiments: Comparison of radiosensitivity due to BNCT/GdNCT (ILL) versus photo-activation radiotherapies (ERSF)
 - ✓ Micro-dosimetry studies by simulation comparing GdNCT and BNCT
 - ✓ Tests of **GdNP** and **BNCT** with thermal neutrons (*ILL*)
 - **Damages on healthy tissues close to tumors :**
 - ✓ Study on the nitrogen present in the DNA as the main source of the dose on healthy tissues

AB-NCT Project

LPSC – Grenoble Team:

D. Santos	<i>(Project Manager, Neutron detection and BSA simulation)</i>
J-F. Muraz	<i>(Technical Coordination, Thermal target tests)</i>
P. Cavalli	<i>(Targets)</i>
D. Dauvergne	<i>(Gamma detection)</i>
R. Delorme	<i>(Simulations, radiobiological experiments)</i>
J. Giraud	<i>(Target thermal and mechanical calculations)</i>
V. Ghetta	<i>(Targets responsibility)</i>
O. Guillaudin	<i>(Neutron detector)</i>
P. Rubiolo	<i>(Simulations and Neutron detection)</i>
N. Sauzet	<i>(Simulations and Neutron detection)</i>

AB-NCT French project strategy

- The NCTs are a subject of **Medical Research** → Physicians and Biologists in France have to define and « build » a clinical research project
- Local (Grenoble) and Regional (Rhône-Alpes) context:
 - LPSC (ion source + accelerator, targets, moderators, neutron and gamma detectors)
 - ILL (U Koester et al.) and ESRF (H. Elleaume, JF Adam et al) Cell irradiation experiments
 - CHU Grenoble (J. Balosso et al)
 - LabEx PRIMES: WP1 Innovative Radiotherapies, WP3 Radiobiology
 - Nanoparticles as carriers
 - Gamma imagery
- National context:
 - Ion sources and RFQs (LPSC, Ganil, Saclay)
 - France Hadron support
- Joining the International effort on AB-NCT
 - Workshop on AB-NCT - Grenoble (October 15th,16th 2015)
 - Collaboration with the Argentina Group: TANDAR (CNEA) A. Kreiner et al.
 - Finland, Germany, Italy, Japan, United Kingdom...

Workshop on Accelerator Based Neutron Capture Therapies (AB-NCT)



October 15-16th, 2015

Laboratoire de Physique Subatomique et de Cosmologie, Grenoble, France

<http://lpsc.in2p3.fr/ab-nct>

Neutron Capture Therapies (NCT) rely on the selective administration of carrying compound that preferentially accumulates in tumour cells. Irradiation with a neutron beam induces lethal doses delivered to tumour tissues by reaction on carriers.

Prospects of expanding NCT require the implementation of neutron sources suitable for in-hospital sitting; then Accelerator-Based (AB) neutron sources are the best choice for this purpose. The aim of this workshop is to gather specialists of scientific domains involved in these innovative therapies to discuss the opportunity to develop a dedicated project in FRANCE along with the possible strategies.



Local Organization Committee:

Denis Dauvergne, Véronique Ghetta,
Julien Giraud, Jean-François Muraz,
Jocelyne Riffault, Pablo Rubiolo, Daniel Santos

Workshop on AB-NCT

October 15th, 16th 2015

Grenoble (France)

More than 50 participants...

